Evidence map›Paper›PMID 16118250›Full record

ArticleAmerican journal of physiology. Endocrinology and metabolism2006

Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression.

Neda Rasouli, Aiwei Yao-Borengasser, Leslie M Miles, Steven C Elbein, Philip A Kern

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in American journal of physiology. Endocrinology and metabolism, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00108615. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00108615 phase4completed

Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance

Ran2004Enrolled48Registered outcomes2Posted comparisons0ConditionsDiabetes, Glucose Metabolism DisordersArmsCT scans, Metformin, Oral glucose tolerance test, Pioglitazone
Open the trial in the graph
3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 115 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Prospects of potential adipokines as therapeutic agents in obesity-linked atherogenic dyslipidemia and insulin resistance.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2023
    Review
  7. Article
  8. Review
  9. Autologous fat transplants to deliver glitazone and adiponectin for vasculoprotection.Journal of controlled release : official journal of the Controlled Release Society · 2017
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Assembly of adiponectin oligomers.Reviews in endocrine & metabolic disorders · 2014
    Review
  15. Article
  16. Article
  17. Vanadyl acetylacetonate upregulates PPARγ and adiponectin expression in differentiated rat adipocytes.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2013
    Article
  18. Article
  19. Vascular biology of metabolic syndrome.Journal of vascular surgery · 2011
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Neda RasouliCentral Arkansas Veterans Healthcare System, 111J LR, 4300 West 7th St., Little Rock, AR 72205, USA. Rasoulineda@uams.edu
Aiwei Yao-Borengasser
Leslie M Miles
Steven C Elbein
Philip A Kern
University of Arkansas for Medical Sciences · USCentral Arkansas Veterans Healthcare System · US

Funding

Verruca Vulgaris--Skin Test &Candida /Mumps AntigenM01RR014288 · NCRR · UNIV OF ARKANSAS FOR MED SCIS · PI PONNAPPAN, USHA · 1999 to 2006
$11.1M
Regulation of lipoprotein lipase in adipocytesR37DK039176 · NIDDK · UNIV OF ARKANSAS FOR MED SCIS · PI KERN, PHILIP A · 2006 to 2011
$1.8M
REGULATION OF LIPOPROTEIN LIPASE IN HUMAN ADIPOCYTESR01DK039176 · NIDDK · UNIVERSITY OF ARKANSAS MED SCIS LTL ROCK · PI KERN, PHILIP A · 1993 to 2005
$1.6M
REGULATION OF LIPOPROTEIN LIPASE IN HUMAN ADIPOCYTESR29DK039176 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI KERN, PHILIP A · 1988 to 1990
–
NCRR NIH HHS M01 RR-14288NIDDK NIH HHS DK-39176
6 · The paper itself

Abstract

Plasma levels of adiponectin are lower in obese and insulin-resistant subjects compared with lean and insulin-sensitive ones. Thiazolidinediones increase plasma adiponectin levels in diabetic subjects, although the mechanism of this increased plasma adiponectin has not been well studied. In the present study, we compared the plasma levels and adipose tissue expression of adiponectin in subjects with normal (NGT) and impaired glucose tolerance (IGT) and also studied the effects of metformin and pioglitazone on plasma and adipose tissue mRNA level of adiponectin in IGT subjects. IGT subjects had lower plasma adiponectin levels compared with NGT subjects, and similarly IGT subjects had lower adiponectin mRNA levels. In contrast, the increased plasma levels of adiponectin in response to pioglitazone were not associated with increased adiponectin expression in adipose tissue. Metformin did not cause any change in plasma or expression levels of adiponectin. Other adipokines were examined, and both pioglitazone and metformin decreased plasma levels of resistin in IGT subjects, and pioglitazone (but not metformin) decreased plasma levels of leptin. These data suggest that pioglitazone increases plasma adiponectin levels by posttranscriptional regulation in contrast to transcriptional regulation of adiponectin in relation to insulin sensitivity in NGT vs. IGT subjects.

Indexed as

Abdominal FatAdiponectinAdultBlood GlucoseFemaleGene ExpressionGlucose IntoleranceGlucose Tolerance TestHumansHypoglycemic AgentsInsulinLeptinMetforminMiddle AgedPioglitazoneResistinAdiponectinADIPOQ protein, humanBlood GlucoseHypoglycemic AgentsInsulinLeptinMetforminPioglitazoneResistinThiazolidinediones

Identifiers

PMID16118250
OpenAlexW2106333594

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.